Skip to main content

Table 2 Adverse events recorded during systemic oncological treatment

From: Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

 

All (N = 363)

SARS-CoV-2 positive* (N = 22)

SARS-CoV-2 negative $ (N = 341)

P

Any toxicity

295 (81%)

19 (83%)

276 (81%)

0.778

Hematological toxicity

135 (37%)

16 (73%)

119 (35%)

< 0.001

Grade 1–2

78 (22%)

10 (46%)

68 (20%)

 

Grade 3–4

56 (16%)

6 (27%)

50 (15%)

 

Neutropenia

 Grade 1–2

27 (7%)

5 (23%)

22 (7%)

 

 Grade 3–4

32 (9%)

4 (18%)

28 (8%)

 

 Febrile neutropenia

7 (2%)

1 (5%)

6 (2%)

 

Lymphopenia

 Grade 1–2

49 (14%)

6 (27%)

43 (13%)

 

 Grade 3–4

28 (8%)

4 (18%)

24 (7%)

 

Thrombopenia

 Grade 1–2

46 (13%)

5 (23%)

41 (12%)

 

 Grade 3–4

3 (1%)

0

3 (1%)

 

 Bleeding event

0

0

0

 

Biological toxicity

117 (32%)

10 (45%)

107 (31%)

0.238

 Grade 1–2

107 (30%)

9 (41%)

98 (29%)

 

 Grade 3–4

9 (3%)

1 (4%)

8 (3%)

 

ALT or AST increased

 Grade 1–2

52 (14%)

4 (18%)

48 (14%)

 

 Grade 3–4

3 (1%)

0

3 (1%)

 

alkaline phosphatase increased

 Grade 1–2

61 (17%)

3 (14%)

58 (17%)

 

 Grade 3–4

4 (1%)

0

4 (1%)

 

Blood bilirubin increased

 Grade 1–2

9 (3%)

0

9 (3%)

 

 Grade 3–4

2 (1%)

0

2 (1%)

 

 Creatinine increased

 Grade 1–2

23 (6%)

2 (9%)

21 (6%)

 

 Grade 3–4

3 (1%)

1 (5%)

2 (1%)

 

General adverse events

235 (65%)

12 (55%)

223 (65%)

0.358

 Grade 1–2

227 (63%)

10 (46%)

217 (64%)

 

 Grade 3–4

8 (2%)

2 (9%)

6 (2%)

 

Fatigue

 Grade 1–2

194 (53%)

10 (46%)

184 (54%)

 

 Grade 3–4

2 (1%)

0

2 (1%)

 

Peripheral neuropathy

 Grade 1–2

101 (28%)

5 (23%)

96 (28%)

 

 Grade 3–4

3 (1%)

2 (9%)

1 (0.3%)

 

Rash (acneiform or maculo-papular)

 Grade 1–2

71 (120%)

4 (18%)

67 (20%)

 

Digestive tract toxicity

143 (39%)

10 (46%)

133 (39%)

0.654

 Grade 1–2

139 (38%)

9 (41%)

130 (38%)

 

 Grade 3–4

4 (1%)

1 (5%)

3 (1%)

 

Nausea

 Grade 1–2

83 (23%)

6 (27%)

77 (23%)

 

 Grade 3–4

1 (0.3%)

1 (5%)

0

 

Vomiting

 Grade 1–2

19 (5%)

2 (9%)

17 (5%)

 

 Grade 3–4

1 (0.3%)

1 (5%)

0

 

Diarrhea

 Grade 1–2

90 (25%)

6 (27%)

84 (25%)

 

 Grade 3–4

4 (1%)

1 (5%)

3 (1%)

 

Infection α

14 (4%)

1 (5%)

13 (4%)

 

 Airway tract

4 (1%)

0

4 (1%)

 

Anti-cancer treatment delay

79 (22%)

12 (55%)

67 (20%)

< 0.001

Duration

 median (days)

14

14

11

 

 Interquartile range (days)

7–15

7–21

7–15

0.504

  1. * Defined as patients with SARS-CoV-2 detected by serology or RT-PCR. $ Defined as patients with a negative serology test and either a negative RT-PCR or no RT-PCR performed
  2. α Of any type other than COVID-19. ALT alanine aminotransferase, AST aspartate transaminase; COVID-19: The viral pandemic coronavirus disease 2019; SARS-CoV-2 severe acute respiratory syndrome coronavirus-2; Adverse events graded according to Common Terminology Criteria for Adverse Events version 5.0
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us